RetinaLogik – a Calgary-based company – announced it has successfully completed a $1.1 million funding round and has received Health Canada’s Class II medical device approval for its technology.
These milestones will advance the adoption of RetinaLogik’s VR-AI-powered platform, enabling eye care professionals to perform essential tests—including visual field exams—more efficiently while enhancing the patient experience with a portable headset.
This device, which is ISO-13485 and MDSAP Certified as well as FDA registered, is designed with patient comfort in mind, offering a streamlined testing process that significantly reduces both the time required for exams and the cost of equipment. And the RetinaLogik system can reduce upfront costs by up to 90% compared to traditional equipment. It also features multilingual support, helping to bridge communication gaps in the clinic.
With these milestones, RetinaLogik also reaffirmed its commitment to advancing high-quality vision screening and monitoring to provide more insights for specialists. And the company plans to expand adoption of its platform across North America and beyond, helping to close critical gaps in eye care.
By enabling earlier detection and treatment of vision-threatening conditions, RetinaLogik looks to prevent irreversible vision loss and improve patient outcomes.
KEY QUOTES:
“Achieving these milestones marks a proud moment for our organization. We’ve developed a solution that not only makes eye care more efficient but also more affordable and accessible. With the support of our investors and partners, we’re excited to continue growing and improving the future of eye care for everyone. This is just the start, stay tuned for more!”
- Dr. Sarhan, CEO of RetinaLogik
“We have proudly supported the RetinaLogik team since their earliest stages and are thrilled to deepen our commitment by doubling down on our investment in the company. Over the past two years, the RetinaLogik team has built a groundbreaking VR platform that delivers unparalleled clinical reliability for functional eye exams.”
- Nikhil Bedi, Operating Partner, UCeed Funds
“Spring Impact Capital is proud to have co-led this round for RetinaLogik, which is proving strong market demand for its product. By enhancing access to quality eye care diagnostics and improving clinic efficiency, they are set to make a meaningful impact on communities while achieving commercial success. We’re excited to support Abdullah, Julia, and the team in this next phase.”
- Graham Day, Managing Partner, Spring Impact Capital
“Alberta Innovates congratulates RetinaLogik on obtaining it’s Health Canada Class II licence through support from the Accelerating Innovations into CarE (AICE) program. This accomplishment is an example of Alberta’s success commercializing health innovation to improve the patient experience and enable easier patient care access in the community.”
- Trevor Lynn, Vice President of Health in Alberta Innovates
